# Contrast-Induced Nephropathy and Nephrotoxins

## Introduction

Nephrotoxic exposure accounts for approximately 20 percent of acute kidney injury in hospitalized patients, representing a significant and potentially preventable source of renal morbidity. Drug-induced AKI can often be avoided or mitigated through awareness of nephrotoxic mechanisms, appropriate dose adjustment, vigilant monitoring, and judicious avoidance of high-risk agents in vulnerable populations. Contrast-induced nephropathy, one of the most frequently discussed nephrotoxic entities, has been the subject of significant recent controversy regarding its true incidence and clinical impact, prompting a fundamental reassessment of long-standing preventive practices.

## Contrast-Induced Nephropathy

### Definition and Epidemiology

Contrast-induced nephropathy is traditionally defined as a rise in serum creatinine of 0.5 mg/dL or more, or an increase of 25 percent or more above baseline, occurring within 48 to 72 hours of contrast administration. The incidence varies widely depending on the patient population studied, ranging from less than 2 percent in the general population to 5 to 20 percent in high-risk patients with pre-existing CKD and diabetes, and as high as 30 percent in patients with an eGFR below 30 and concurrent diabetes. The need for dialysis following contrast exposure remains low overall at less than 1 percent, though this risk is higher in patients with pre-existing kidney disease.

### Pathophysiology

The pathophysiology of contrast-induced nephropathy involves multiple synergistic mechanisms. Contrast media cause medullary vasoconstriction through the release of endothelin and adenosine, producing ischemic injury to the metabolically vulnerable outer medullary region. Direct tubular toxicity results from osmotic injury to tubular epithelial cells, oxidative stress from reactive oxygen species generation, and cytoplasmic vacuolization. The contrast-induced osmotic diuresis paradoxically increases oxygen consumption in the thick ascending limb, worsening the supply-demand mismatch in the outer medulla. Rheological effects, including increased blood viscosity and red cell aggregation, further impair medullary microcirculation.

### Controversy: Contrast-Induced vs Contrast-Associated AKI

Recent large observational studies, including the AMACING trial and multiple propensity-matched analyses, have challenged the historical paradigm by suggesting that the risk of contrast-induced nephropathy has been substantially overestimated. A fundamental methodologic flaw in many earlier studies was the absence of control groups receiving no contrast, making it impossible to distinguish true contrast nephrotoxicity from background rates of AKI in acutely ill populations. The distinction between intravenous and intra-arterial contrast is now recognized as clinically important, with intravenous contrast appearing to have considerably lower nephrotoxicity than intra-arterial contrast administered during cardiac catheterization. The 2020 ACR/NKF consensus statement established that the eGFR threshold for clinically significant CIN risk is 30 mL/min for intravenous contrast, meaning that risk is minimal above this level, and 30 to 45 mL/min for intra-arterial contrast. Critically, concern about contrast nephropathy should not deter clinicians from performing emergent contrast-enhanced imaging when the diagnostic information is clinically necessary.

### Risk Factors

Pre-existing chronic kidney disease, particularly an eGFR below 30 mL/min/1.73m2, is the strongest predictor of contrast-induced nephropathy. Diabetes mellitus amplifies risk primarily in the setting of concurrent CKD. Volume depletion, congestive heart failure with hemodynamic instability, and concurrent nephrotoxin exposure from NSAIDs or aminoglycosides further increase vulnerability. The risk is dose-dependent, increasing with contrast volume, and guidelines recommend keeping the total contrast volume below 100 mL or maintaining a volume-to-creatinine clearance ratio below 3.7. The iodine content and osmolality of the contrast agent also influence risk, with high-osmolar agents carrying the greatest nephrotoxic potential. Multiple myeloma has traditionally been considered a risk factor due to the theoretical concern of exacerbating cast nephropathy and dehydration, though modern evidence suggests the risk is lower than historically perceived with adequate hydration.

### Prevention

Volume expansion remains the most effective and best-validated preventive strategy for contrast-induced nephropathy. Isotonic sodium chloride at a rate of 1 to 1.5 mL/kg/hr for 6 to 12 hours before and 6 to 12 hours after contrast administration is the standard protocol. The PRESERVE trial, published in 2017, definitively demonstrated that sodium bicarbonate confers no benefit over normal saline, and that oral N-acetylcysteine provides no benefit over placebo, effectively eliminating both agents from the CIN prevention toolkit. The POSEIDON trial demonstrated a role for left ventricular end-diastolic pressure-guided fluid administration during cardiac catheterization.

Low-osmolar or iso-osmolar contrast agents should be used preferentially, and high-osmolar agents should be avoided. Minimizing contrast volume through techniques such as biplane imaging and avoiding ventriculography when not essential further reduces risk. Some data support periprocedural high-dose statin therapy, with atorvastatin 80 mg showing benefit in the PRATO-ACS trial, though the evidence remains inconsistent across studies. Metformin should be held for 48 hours after contrast exposure in patients with an eGFR below 30 to prevent lactic acidosis in the event that AKI develops, and creatinine should be checked before the drug is resumed. NSAIDs and diuretics should be withheld when possible to optimize volume status before the procedure.

<image>Risk stratification tool for contrast-induced nephropathy presented as a clinical scoring system. Show a point-based system incorporating: hypotension (5 points), IABP use (5 points), CHF class III-IV (5 points), age >75 (4 points), anemia (3 points), diabetes (3 points), contrast volume (1 point per 100 mL), and creatinine/eGFR-based scoring (2-6 points based on severity). Show risk categories: low (≤5 points, <7.5% risk), moderate (6-10 points, 14% risk), high (11-15 points, 26% risk), very high (≥16 points, 57% risk). Include a separate panel showing the PRESERVE trial results demonstrating no benefit of NAC or NaHCO3 over saline alone.</image>

## Aminoglycoside Nephrotoxicity

### Mechanism

Aminoglycosides accumulate in proximal tubular cells through megalin-mediated endocytosis from the tubular lumen. Once internalized, these polycationic molecules concentrate in lysosomes, where they disrupt lysosomal membranes and trigger a cascade of cellular injury culminating in tubular necrosis. The clinical presentation is characteristically non-oliguric ATN with polyuria, hypokalemia, hypomagnesemia, and a urinary concentrating defect, reflecting injury to the proximal tubule and medullary structures. The risk of nephrotoxicity increases with cumulative dose and duration of therapy, typically becoming clinically apparent after 5 to 7 days of treatment.

### Prevention and Monitoring

Extended-interval, or once-daily, dosing represents a major advance in reducing aminoglycoside nephrotoxicity. This dosing strategy exploits the concentration-dependent bactericidal activity and prolonged post-antibiotic effect of aminoglycosides while allowing tubular cells sufficient recovery time between exposures to clear accumulated drug. The Hartford nomogram guides extended-interval dosing and monitoring. Trough levels should be monitored, with a target below 1 mcg/mL for gentamicin and tobramycin. Concurrent nephrotoxins should be avoided, euvolemia should be maintained, and the duration of therapy should be limited to the shortest effective course.

## Vancomycin Nephrotoxicity

### Mechanism

Vancomycin nephrotoxicity results from oxidative stress and proximal tubular mitochondrial dysfunction. The risk of AKI increases substantially with trough levels exceeding 15 to 20 mcg/mL and with concurrent administration of other nephrotoxins. The 2020 IDSA guidelines recommend a paradigm shift from trough-based to AUC/MIC-guided dosing, with a target AUC of 400 to 600 mg multiplied by hours per liter, which reduces AKI by approximately 40 percent compared to trough-guided dosing while maintaining therapeutic efficacy.

### Vancomycin + Piperacillin-Tazobactam

Multiple studies, including the ACORN trial published in 2024, have confirmed an increased risk of AKI with the combination of vancomycin and piperacillin-tazobactam compared to vancomycin combined with cefepime. The mechanism may involve competition for organic anion transporter-mediated tubular secretion (OAT1/OAT3) or direct synergistic tubular toxicity. This evidence supports preferring cefepime or meropenem as the beta-lactam partner when vancomycin is clinically indicated.

## Calcineurin Inhibitor (CNI) Nephrotoxicity

### Acute CNI Toxicity

Acute calcineurin inhibitor toxicity results from dose-dependent afferent arteriolar vasoconstriction, mediated by increased endothelin-1 and thromboxane A2 production, which reduces glomerular filtration rate. This hemodynamic effect is reversible with dose reduction. Rarely, calcineurin inhibitors can trigger thrombotic microangiopathy through complement activation and endothelial injury, a serious complication that may necessitate drug discontinuation.

### Chronic CNI Nephropathy

Chronic calcineurin inhibitor nephropathy represents an irreversible and progressive form of kidney injury characterized by arteriolar hyalinosis with pathognomonic nodular hyaline deposits in the walls of afferent arterioles. Interstitial fibrosis and tubular atrophy develop in a characteristic "striped fibrosis" pattern on biopsy, reflecting the ischemic injury downstream of the affected arterioles. Management strategies include CNI minimization protocols, conversion to belatacept in transplant recipients, or substitution with mTOR inhibitors, though each approach carries its own trade-offs.

## NSAID Nephrotoxicity

### Hemodynamic AKI

NSAIDs inhibit prostaglandin-mediated vasodilation of the afferent arteriole, a compensatory mechanism that is particularly critical for maintaining glomerular filtration in states of reduced effective arterial blood volume. Risk factors for NSAID-induced hemodynamic AKI include pre-existing CKD, congestive heart failure, hepatic cirrhosis, volume depletion, and concurrent use of ACE inhibitors or ARBs and diuretics. The injury is usually reversible with drug discontinuation.

### Other NSAID Renal Effects

NSAIDs produce a broader spectrum of renal toxicity beyond hemodynamic AKI. Acute interstitial nephritis from NSAIDs is notable for its frequent association with concurrent minimal change disease and nephrotic-range proteinuria, a combination that is more characteristic of NSAID-induced AIN than AIN from other drug classes. Sodium and water retention antagonizes the effects of diuretics and worsens hypertension and heart failure. Hyperkalemia results from reduced renin and aldosterone secretion combined with impaired potassium excretion. Chronic, high-dose NSAID use can cause renal papillary necrosis, identified by the characteristic "ring sign" on intravenous pyelography, and constitutes the pathologic entity of analgesic nephropathy.

## Other Important Nephrotoxins

### Cisplatin

Cisplatin produces dose-dependent proximal tubular injury through DNA cross-linking, mitochondrial dysfunction, and oxidative stress. The clinical syndrome includes AKI, hypomagnesemia from renal magnesium wasting, and salt wasting. Prevention centers on aggressive pre- and post-hydration with normal saline, typically 1 liter or more before and after each dose. Amifostine, a thiol-based cytoprotectant, has limited clinical use due to its own side effect profile.

### Tenofovir (TDF, not TAF)

Tenofovir disoproxil fumarate causes proximal tubular toxicity that can manifest as the full Fanconi syndrome, with glucosuria, phosphaturia, aminoaciduria, and type 2 renal tubular acidosis. Monitoring should include urine glucose, serum phosphorus, and creatinine. If toxicity develops, switching to tenofovir alafenamide (TAF), which achieves lower plasma levels with equivalent intracellular antiviral activity, typically resolves the tubular dysfunction.

### Lithium

Lithium produces nephrogenic diabetes insipidus in up to 40 percent of long-term users by entering collecting duct principal cells through ENaC and inhibiting glycogen synthase kinase-3 beta, which leads to downregulation of aquaporin-2 water channels. Chronic lithium use also causes tubulointerstitial nephritis progressing to CKD that may become irreversible after prolonged exposure. Additional renal effects include distal (type 1) renal tubular acidosis and hypercalcemia from lithium-induced hyperparathyroidism. Amiloride blocks lithium entry through ENaC and may ameliorate the diabetes insipidus while potentially protecting against further tubular injury. Creatinine and concentrating ability should be monitored regularly in all patients on long-term lithium therapy, with the recognition that CKD risk increases 1.5- to 2-fold with more than 10 to 15 years of use.

### Immune Checkpoint Inhibitors (ICIs)

Immune checkpoint inhibitor nephrotoxicity has become increasingly common as the use of PD-1, PD-L1, and CTLA-4 inhibitors has expanded across oncologic indications. Acute interstitial nephritis is the most common renal manifestation, occurring more frequently with PD-1 inhibitors than with CTLA-4 inhibitors, with a median onset of 3 to 12 months after initiation. Patients may present with AKI and either a bland or WBC cast-containing urine sediment. Renal biopsy is recommended to confirm the diagnosis before initiating high-dose corticosteroids, as the differential includes other causes of AKI in cancer patients. Treatment consists of holding the checkpoint inhibitor and administering prednisone at 1 mg/kg with a taper over 4 to 8 weeks. Most patients recover renal function, though some develop chronic kidney disease.

<image>Comprehensive table summarizing major nephrotoxic drugs organized by mechanism of renal injury. Create five columns: (1) Hemodynamic AKI (NSAIDs, ACEi/ARBs, calcineurin inhibitors, iodinated contrast), (2) Acute tubular necrosis (aminoglycosides, cisplatin, amphotericin B, contrast, myoglobin), (3) Acute interstitial nephritis (penicillins, NSAIDs, PPIs, checkpoint inhibitors, allopurinol), (4) Crystal nephropathy (acyclovir, methotrexate, indinavir, tumor lysis syndrome), and (5) Osmotic nephropathy (IV immunoglobulin with sucrose, mannitol, hydroxyethyl starch). For each drug, include the clinical presentation, key diagnostic findings, prevention strategy, and treatment. Use icons to indicate reversibility (fully reversible, partially reversible, irreversible).</image>

| Nephrotoxin | Mechanism | Clinical Presentation | Prevention/Monitoring | Key Clinical Pearl |
|------------|-----------|----------------------|----------------------|-------------------|
| Aminoglycosides | Proximal tubular accumulation via megalin; lysosomal disruption → ATN | Non-oliguric ATN, hypoK, hypoMg, concentrating defect (day 5–7) | Extended-interval dosing; trough <1 mcg/mL; limit duration | Once-daily dosing reduces nephrotoxicity |
| Vancomycin | Proximal tubular oxidative stress; mitochondrial dysfunction | AKI; risk ↑ with trough >15–20 mcg/mL | AUC/MIC-guided dosing (target 400–600); avoid pip-tazo combo | AUC dosing reduces AKI ~40% vs trough-based |
| NSAIDs | Afferent arteriolar vasoconstriction (block PGE2) | Hemodynamic AKI; AIN + MCD; Na/K retention; papillary necrosis | Avoid in CKD, CHF, volume depletion; avoid "triple whammy" | AIN from NSAIDs uniquely associated with concurrent MCD |
| Calcineurin inhibitors | Afferent vasoconstriction (acute); arteriolar hyalinosis + striped fibrosis (chronic) | Acute: reversible ↓ GFR; Chronic: irreversible CKD | Drug level monitoring; CNI minimization protocols | "Striped fibrosis" is pathognomonic on biopsy |
| Cisplatin | DNA cross-linking; mitochondrial dysfunction; oxidative stress | AKI, hypoMg (renal wasting), salt wasting | Aggressive pre/post hydration with NS | HypoMg can persist long after cisplatin discontinued |
| Tenofovir (TDF) | Proximal tubular toxicity → Fanconi syndrome | Glucosuria, phosphaturia, aminoaciduria, type 2 RTA | Monitor urine glucose, serum phosphorus, creatinine | Switch to TAF if toxicity develops |
| Lithium | ENaC-mediated entry → AQP2 downregulation; chronic TIN | Nephrogenic DI (40% of users); CKD; type 1 RTA | Amiloride (blocks Li entry via ENaC); monitor Cr regularly | CKD risk ↑ 1.5–2× with >10–15 years use |
| Checkpoint inhibitors (ICIs) | Immune-mediated AIN | AKI; median onset 3–12 months | Hold ICI; prednisone 1 mg/kg with taper | Biopsy recommended before starting steroids |

### Crystal Nephropathy

Acyclovir and valacyclovir cause intratubular crystal obstruction, preventable with adequate hydration and slow intravenous infusion rates. Methotrexate crystallizes in acidic urine, and prevention requires urine alkalinization to maintain a pH above 7, leucovorin rescue, and aggressive hydration; glucarpidase provides enzymatic cleavage of methotrexate in cases of toxic serum levels. Indinavir causes crystalluria and nephrolithiasis, mitigated by ensuring adequate hydration. Tumor lysis syndrome produces AKI through uric acid and calcium phosphate crystal deposition in renal tubules. Prevention in high-risk malignancies employs rasburicase, a recombinant urate oxidase that rapidly converts uric acid to the highly soluble allantoin, combined with aggressive hydration and allopurinol. Rasburicase is absolutely contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency because the hydrogen peroxide generated during urate oxidation triggers hemolytic anemia.

### Osmotic Nephropathy

Intravenous immunoglobulin preparations stabilized with sucrose cause osmotic tubular injury, and sucrose-free formulations should be used in patients with CKD. Hydroxyethyl starch produces osmotic nephropathy and was associated with increased AKI and mortality in critically ill patients in the CHEST and 6S trials, leading to its virtual abandonment in clinical practice. Mannitol causes osmotic nephrosis at high cumulative doses through proximal tubular cell swelling.

## Key Clinical Pearls

- The PRESERVE trial definitively eliminated NAC and sodium bicarbonate from the CIN prevention toolkit; isotonic saline hydration remains the only proven preventive strategy
- The true risk of CIN with modern low-osmolar contrast in patients with eGFR >30 is very low; never withhold essential contrast-enhanced imaging due to exaggerated CIN concerns
- Vancomycin + piperacillin-tazobactam significantly increases AKI risk compared to vancomycin + cefepime; choose the beta-lactam partner wisely (ACORN trial)
- AUC-guided vancomycin dosing (target 400-600) is the current standard; trough-based dosing overexposes patients and increases nephrotoxicity
- Immune checkpoint inhibitor nephrotoxicity is increasingly common; maintain a high index of suspicion for AIN in patients on ICIs presenting with unexplained AKI

## References
1. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine (PRESERVE). *N Engl J Med*. 2018;378(7):603-614.
2. Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline. *Am J Health Syst Pharm*. 2020;77(11):835-864.
3. Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2018;46(1):12-20.
4. Perazella MA. Drug-induced acute kidney injury: diverse mechanisms of tubular injury. *Curr Opin Crit Care*. 2019;25(6):550-557.
5. ACR-NKF Consensus Statement on the Use of Iodinated and Gadolinium-Based Contrast Media in Patients with Kidney Disease. *Radiology*. 2020;294(3):660-668.